How much capital does BeiGene intend to raise from this offering?

BeiGene intends to raise approximately $650 million before underwriting discounts and commissions and estimated offering expenses. Additionally, the underwriters have a 30-day option to purchase up to an additional $50 million of ADSs.

What is BeiGene's liquidity position as disclosed in this filing?

As of December 31, 2017, BeiGene estimated its cash and cash equivalents and short-term investments to be between $835 million and $840 million. It's important to note that this figure has not been audited or reviewed by independent accountants and could be subject to change.

Where can investors find more detailed information about the offering and the company's business?

Investors can find more detailed information in the preliminary prospectus supplement filed with the SEC, the press release announcing the offering (Exhibit 99.1), updated company disclosures (Exhibit 99.2), and the investor presentation (Exhibit 99.3), all of which are referenced and incorporated by this Form 8-K filing.

ONC/BEIGF 8-K: Earnings & Results

Q: What is the primary purpose of this Form 8-K filing?

The primary purpose of this Form 8-K filing is to announce the commencement of BeiGene, Ltd.'s proposed underwritten public offering of American Depositary Shares (ADSs) and to provide related financial and business updates. It also serves to incorporate updated disclosure materials.

Summary

BeOne Medicines Ltd. (ONC), now referred to as BeiGene, Ltd. in this filing, announced on January 16, 2018, the commencement of a proposed underwritten public offering of American Depositary Shares (ADSs). The company aims to raise approximately $650 million, with an option for underwriters to purchase an additional $50 million in ADSs. This offering is being made under an effective shelf registration statement. In conjunction with the offering, BeiGene disclosed its preliminary cash and cash equivalents and short-term investments position as of December 31, 2017, estimated to be between $835 million and $840 million. This provides investors with a snapshot of the company's liquidity. The filing also indicates that updated business and risk factor disclosures are being provided to prospective investors through a preliminary prospectus supplement, a press release, and a company presentation, which are incorporated by reference.

Key Highlights

1BeiGene, Ltd. announced a proposed public offering to raise approximately $650 million.
2The company has granted underwriters an option to purchase an additional $50 million of ADSs.
3Estimated cash and cash equivalents, plus short-term investments, stood between $835 million and $840 million as of December 31, 2017.
4The offering is being conducted under a previously filed effective shelf registration statement.
5Updated business and risk factor disclosures are provided in supplementary documents.
6The filing includes a press release, updated company disclosure, and investor presentation materials.

BeOne Medicines Ltd. 8-K Report, Financial Results (Jan 16, 2018)

Summary

Key Highlights

Frequently Asked Questions